Additionally, the downregulation of EGR1 is associated with resistance to sorafenib, while the overexpression of EGR1 or EGR1 gene therapy enhances the sensitivity of HCC cells and xenografted tumors to sorafenib. Here, EGR1 is linked to hepatocellular carcinoma.